greeksoup/ stock research
Stock research / United States / AZN / Year to 31 December 2017

AstraZeneca PLC (AZN) annual results, year to 31 December 2017: revenue USD 22,465 million, from the 20-F

AstraZeneca PLC files a 20-F with the SEC once a year, in US dollars. In the year to 31 December 2017 it reported revenue of USD 22,465 million, down 2.3% on the year before. Its profit attributable to shareholders was USD 3,001 million, down 14.2%, and diluted earnings per share USD 2.37.

Revenue
USD 22,465 million
-2.3% on the year
FY2015FY2017
Operating margin
16.4%
21.3% a year earlier
FY2015FY2017
Net income
USD 3,001 million
-14.2% on the year
FY2015FY2017
Diluted EPS
USD 2.37
-14.1% on the year
FY2015FY2017

this yearthe year beforeIn US dollars as filed. Hover a bar for its figure.

Income statement (profit and loss)

Year toDec 2016Dec 2017
Revenue23,00222,465
Cost of sales4,1264,318
Gross profit18,87618,147
Research and development5,8905,757
Selling, general and administrative9,41310,233
Operating profit4,9023,677
Finance costs1,3841,508
Profit before tax3,5522,227
Income tax146-641
Profit for the year3,4062,868
Profit attributable to shareholders3,4993,001
Filing20-F20-F
USD million, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed.
Read moreA line the company does not file under the standard tag is left out rather than estimated.
Year toDec 2016Dec 2017
Diluted EPS2.762.37
Basic EPS2.772.37
Filing20-F20-F

USD per ordinary share, as filed.

Cash flow

Year toDec 2016Dec 2017
Cash from operations4,1453,578
Purchase of property, plant and equipment1,4461,326
Free cash flow2,6992,252
Cash from investing-3,969-2,328
Cash from financing-1,324-2,936
Dividends paid3,5613,519
Filing20-F20-F

USD million. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.

Balance sheet

Year toDec 2016Dec 2017
Funded by
Equity attributable to shareholders14,85414,960
Non-controlling interests1,8151,682
Borrowings, as filed16,80817,807
Other liabilities29,04928,905
Total equity and liabilities62,52663,354
Owned
Property, plant and equipment6,8487,615
Goodwill11,65811,825
Other intangible assets27,58626,188
Cash and cash equivalents5,0183,324
Trade and other receivables4,5735,009
Inventories2,3343,035
Other assets4,5096,358
Total assets62,52663,354
Filing20-F20-F

USD million, at each fiscal year end.

Ratios on the filed lines

Year toDec 2016Dec 2017
Gross margin82.1%80.8%
Operating margin21.3%16.4%
Net margin15.2%13.4%
Free cash flow margin11.7%10.0%
Return on year-end equity23.6%20.1%
Effective tax rate4.1%-28.8%
Filing20-F20-F

Arithmetic on the filed lines of the same year.

20-F for the year to 31 December 2017, filed 3 March 2020: the filing. The figures are in US dollars as filed.